Resources Contact Us Home
Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies

Image Number 12 for United States Patent #7491393.

The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.

  Recently Added Patents
Image surveillance system and method of detecting whether object is left behind or taken away
Antenna device
System, method, and computer program product for identifying unwanted data communicated via a session initiation protocol
Method and apparatus for displaying system status with a wide range of viewing angle
Tray for microwave cooking and folding of a food product
Customizing a range of acceptable tape dimensional stability write conditions
  Randomly Featured Patents
Breech loader packaging systems and associated breech loading chutes and methods
Machine tool capable of changing worn cutting tools, such as small diameter drills, with new ones
Torque magnifying handle for driving tool
High pressure gas compressor
Nandina domestic plant named `Jaytee`
Pinch sensor for sliding door
Database analysis tool
Polymer micromold and fabrication process
Phage-resistant streptococcus